CEA: Carcinoembryonic antigen, VIM: Vimentin, SMA: Smooth muscle antigen, A1AT: a1-antitrypsin, A1ACT: a1-antichymotrypsin
, LYS: Lysozyme, NSE: Neuron specific enolase.
Prostate-specific antigen in serum occurs predominantly in complex with a1-antichymotrypsin.
Serum prostate-specific antigen complexed to a1-antichymotrypsin as an indicator of prostate cancer.
Serum prostate specific antigen complexed to a1-antichymotrypsin as an indicator of prostate cancer.
Prostate-specific antigen and its complexes with a1-antichymotrypsin in the plasma of patients with prostatic disease.
A complex between prostate-specific antigen and a1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer.
In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to a1-antichymotrypsin in blood samples.
Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to a1-antichymotrypsin
production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia.
Amino acid sequence at the reactive site of human a1-antichymotrypsin
PSA, a serine protease, forms complexes with serine protease inhibitors such as [alpha]2-macroglobulin and a1-antichymotrypsin